N/A N=127 Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
Respiratory Disorders
Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=33 The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years
Upper Respiratory Infection · Common Cold
Primary: Local Leukotriene Levels — 440; 368; 440; 619 pg/ml
N/A N=58 The Development of a Human Model of Respiratory Syncytial Virus Infection
Respiratory Syncytial Virus Infections · Respiratory Viral Infections
Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants
Phase 1 N=31 A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Proportion of Subjects Who Discontinue Study Drug Due to Adverse Events — 1; 0 Participants
Phase 4 N=50 Intermittent Use of Aerosolized Ribavirin for Treatment of RSV
Hematological Malignancies
Primary: Occurrences of Pneumonia — 4; 3 Participants
N/A N=103 The Effectiveness of AAD and IPV to Treat Hospitalized Infants (<2years) With Acute Viral Bronchiolitis.
Bronchiolitis
Primary: Length of Hospital Stay — 3.5; 3.6; 4.5 days
N/A N=129 Reducing Length of Stay for Veterans Hospitalized With Pneumonia
Pneumonia
Primary: Length of Hospital Stay — 7.3; 5.8 Days
N/A N=360 Urgent Care Management of Respiratory Illness Enabled With Novel Testing Pathway
Viral Infection · Acute Respiratory Infection · Upper Resp Tract Infection
Primary: Satisfaction With Time to Receive Result — 180; 53; 3; 72 participants
N/A N=75 Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge
Respiratory Syncytial Virus Infections · Influenza, Human
Primary: Total Symptom Score — 29.25; 17.50; 11.00; 13.00 score on a scale
Phase 2 N=29 Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
Corona Virus Infection · SARS-CoV 2 · SARS Pneumonia
Primary: Number of Participants Transferred to Intensive Care Unit (ICU) — 4 Participants
N/A N=75 Urease Breath Test for Rapid Characterization of Pneumonia
Pneumonia, Bacterial
Primary: Adverse Events — 3; 0; 1; 0 Participants
N/A N=203 The Place of Imaging and Microbiology in the Diagnosis of Pneumonia in the Elderly
Pneumonia
Primary: Number of Patients With Modified Diagnosis Probability After Low Dose CT (LDCT) — 10; 3; 4; 34 Participants
N/A N=69 Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19
Covid19
Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants
Phase 3 N=26 Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
Adenovirus Infection · BK Virus Infection · Cytomegalovirus Infections
Primary: Number of Participants Experiencing Clinically Significant Infections or Episodes of End-organ Disease — 3 Participants
N/A N=558 Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
Influenza, Human
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs at Day 3 -- Team Collected Samples — 99; 131 Participants…
Phase 2 N=98 Human Lung Responses to Respiratory Pathogens
Respiratory Infection
Primary: Antimicrobial Activity by Airway Surface Liquid (ASL) as Measured by Relative Light Units (RLU) — -581; -485 Relative Light Units (RLU)
Phase 2 N=311 Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295)
Asthma · Common Cold · Picornavirus Infection
Primary: Percentage of Participants With Rhinovirus PCR-Positive Colds — 2.6; 2.5 percentage of participants — p=0.973
N/A N=1,027 Improving CarE for Community Acquired Pneumonia 1
Pneumonia Childhood
Primary: Exclusive Guideline-Concordant Antibiotic Therapy, First 24 Hours — 255; 284; 174; 120 Participants
Phase 2 N=189 Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection
Respiratory Syncytial Virus Infection
Primary: Time-Weighted Average Change in Respiratory Syncytial Viral (RSV) Load From Baseline to Day 5 — -0.77; -0.89 log10 copies/mL — p=0.46
Phase 2 N=44 Respiratory Syncytial Virus - RSV Protocol
Bone Marrow Transplant Infection · Infection in Marrow Transplant Recipients · Respiratory Syncytial Virus Infections
Primary: Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI) — 8; 30; 10 percentage of participants
Phase 2 N=260 Nitazoxanide Versus Placebo for the Treatment of Hospitalized Subjects With Severe Acute Respiratory Illness
Severe Acute Respiratory Illness
Primary: Time to Hospital Discharge — 7.1; 7.5 Days — p=0.5634
Phase 2 N=38 Clinical Response to Rhinovirus Challenge
Asthma · Allergic Rhinitis
Primary: Change in Symptom Scores Induced by the Rhinovirus Using Jackson Criteria Including Nasal Congestion, Drainage, Cough, Wheezing — 5.0; 4.2; 2.8 score on a scale
Phase 2 N=150 Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A
Influenza
Primary: Assess the Safety and Tolerability of a Single IV Dose of VIS410 in Participants With Uncomplicated Influenza Infection — 57.1; 34.7; 45.9; 26.0 percentage of participants
Phase 4 N=18 Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 0; 17 Participants
Phase 1 N=4 Challenge Infection of Healthy Adult Volunteers With RSV A2
Upper Respiratory Tract Infections
Primary: Participants With Detectable RSV Shedding in Nasopharyngeal Wash — 2; 4 Participants
Phase 2 N=61 Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection
Respiratory Syncytial Virus (RSV)
Primary: Time-Weighted Average Change in Viral Load From Day 1/Baseline Through Day 7 in Participants in the Full Analysis Set — -0.73; -0.90 log10 copies/mL — p=0.72
Phase 2 N=48 Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children
Respiratory Syncytial Virus
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0 participants
N/A N=197 Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and During Acute Exacerbations of the Disease, in Asia Pacific
Respiratory Disorders
Primary: Percentage of Sputum Samples Positive for Bacterial Pathogens as Identified by Bacteriological Methods, in Any Stable COPD Patients and During AECOPDs — 74.2; 78; 94.6…
N/A N=536 Improving CarE for Community Acquired Pneumonia 1 (ICE-CAP2)
Pneumonia Childhood
Primary: Inappropriate Disposition — 7; 6 Participants
Phase 3 N=181 Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Serotype Opsonization Titers — 10.85; 12.63; 132.51; 908.23 titers